Prot #M16-045: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis

Project: Research project

Project Details

StatusActive
Effective start/end date2/4/191/31/23

Funding

  • AbbVie Inc. (Prot #M16-045)